Idursulfase
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
  (what is this?) (verify) | |
Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4]
References
- ↑ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. PMID 17459751. doi:10.1016/j.ymgme.2007.03.003.
- ↑ "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
- ↑ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
- ↑ , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
External links
- idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.